CRT-D Cost-Effectiveness Disputed; JACC Editorial Says More Studies Needed
This article was originally published in The Gray Sheet
Executive Summary
Additional head-to-head trials are necessary to assess whether the benefit of cardiac resynchronization therapy with defibrillation (CRT-D) justifies its high cost, according to Mark Hlatky, MD, Stanford University